Isoimperatorin regulates hepatic fibrosis through LXRα/β-HMGB1/NLRP3 axis: insights into the apoptosis of activated hepatic stellate cells in hepatic microenvironment

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Hepatic fibrosis is a pathological response to persistent liver injury, characterized by activation of hepatic stellate cells (HSCs) and excessive extracellular matrix (ECM) deposition. Isoimperatorin (ISOIM), a coumarin derivative isolated from Angelica dahurica, has been reported to possess analgesic and anti-inflammatory properties. This study investigated the hepatoprotective potential of ISOIM and its underlying mechanisms against hepatic fibrosis. C57BL/6J mice were intraperitoneally injected with thioacetamide (TAA, 100−200 mg·kg⁻¹) for 5 weeks and received ISOIM (5 or 8 mg·kg⁻¹) administration. HSCs and LX-2 were stimulated with transforming growth factor-β (TGF-β, 10 nmol·L⁻¹) or conditioned medium from lipopolysaccharide (LPS)-primed THP-1 (LPS-MØ-CM), followed by ISOIM (0.78, 1.56, 3.125 μmol·L⁻¹) treatment. In TAA-induced mice, ISOIM reduced serum transaminases, attenuated ECM deposition and histopathological damage, alleviated inflammatory responses, and decreased hepatocyte apoptosis. In activated HSCs, ISOIM inhibited ECM accumulation, reduced inflammatory cytokine expression and promoted apoptotic signaling. Mechanistically, ISOIM showed a potential interaction with LXRα/β, reduced HMGB1-associated inflammatory signaling, and suppressed activation of the HMGB1/NLRP3 signaling, accompanied by enhanced caspase-3-mediated apoptotic signaling in activated HSCs. These effects were consistent with those of the LXRα/β agonist GW3965 and were markedly attenuated by LXRβ or LXRα silencing. In addition, ISOIM regulated LXRα/β and the HMGB1-NLRP3 axis, reduced α-SMA expression, and promoted apoptotic signaling in LX-2 cultured with LPS-MØ-CM. Collectively, ISOIM exerted hepatoprotective effects by activating LXRα/β, inhibiting HMGB1/NLRP3 signaling, and promoting apoptosis of activated HSCs within the hepatic microenvironment.

Keywords

Isoimperatorin / Hepatic fibrosis / Hepatic microenvironment / LXRα/β / HMGB1-NLRP3 / Apoptosis

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Pei Q, Yi Q, Tang L . Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities. Int J Mol Sci. 2023; 24(11):9671. https://doi.org/10.3390/ijms24119671.

[2] Jiang Y, Hou L, Dou J, et al. Sesamol as a potential candidate for the treatment of hepatic fibrosis, based on its regulation of FXR/LXR axis-mediated inhibition of autophagy through crosstalk between hepatic cells and macrophage. Phytomedicine. 2024; 123:155145. https://doi.org/10.1016/j.phymed.2023.155145.

[3] Zhao T, Zhong G, Wang Y, et al. Pregnane X receptor activation in liver macrophages protects against endotoxin-induced liver injury. Adv Sci (Weinh). 2024; 11(19):e2308771. https://doi.org/10.1002/advs.202308771.

[4] Zhang N, Yao H, Zhang Z, et al. Ongoing involvers and promising therapeutic targets of hepatic fibrosis: the hepatic immune microenvironment. Front Immunol. 2023; 14:1131588. https://doi.org/10.3389/fimmu.2023.1131588.

[5] Friedman SL, Pinzani M . Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology. 2022; 75(2):473-488. https://doi.org/10.1002/hep.32285.

[6] Liu L, Li B, Zhang Y, et al. MFAP4 deficiency attenuates liver fibrosis by regulating hepatic stellate cell fate through inhibition of the FAK/PI3K/NFκB signaling pathway. Cell Mol Gastroenterol Hepatol. 2025; 19(10):101548. https://doi.org/10.1016/j.jcmgh.2025.101548.

[7] Wang L, Huang Y, Chen J, et al. Dynamic crosstalk between HSCs and liver microenvironment: multicellular interactions in the regulation of liver fibrosis. Front Cell Dev Biol. 2025; 13:1635763. https://doi.org/10.3389/fcell.2025.1635763.

[8] Ge X, Desert R, Magdaleno F, et al. Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice. J Hepatol. 2024; 80(3):482-494. https://doi.org/10.1016/j.jhep.2023.11.005.

[9] Ma X, Qiu J, Zou S, et al. The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies. Front Immunol. 2024; 15:1494250. https://doi.org/10.3389/fimmu.2024.1494250.

[10] Zhu L, Tong H, Ren C, et al. Inflammation unleashed: the role of pyroptosis in chronic liver diseases. Int Immunopharmacol. 2024; 141:113006. https://doi.org/10.1016/j.intimp.2024.113006.

[11] Tseng HF, Chao HN, Lin CH, et al. Danshensu attenuates palmitic acid-induced activation of hepatic stellate cells by regulating pyroptosis. Int J Med Sci. 2025; 22(8):1865-1874. https://doi.org/10.7150/ijms.107564.

[12] Dou JY, Liu SH, Guo J, et al. Dietary supplementation of pterostilbene, a major component in small berries, prevents alcohol-induced liver injury associated with lipid accumulation and inflammation. Food Funct. 2024; 15(22):11206-11219. https://doi.org/10.1039/d4fo03898c.

[13] Dou JY, Cui ZY, Xuan MY, et al. Diallyl disulfide, the bioactive component of Allium species, ameliorates pulmonary fibrosis by mediating the crosstalk of farnesoid X receptor and yes-associated protein 1 signaling pathway. Phytother Res. 2024; 38(8):4009-4021. https://doi.org/10.1002/ptr.8268.

[14] Cai L, Yin M, Peng S, et al. RXRα modulates hepatic stellate cell activation and liver fibrosis by targeting CaMKKβ-AMPKα axis. Acta Pharm Sin B . 2025; 15(7):3611-3631. https://doi.org/10.1016/j.apsb.2025.05.023.

[15] Lockhart SM, Muso M, Zvetkova I, et al. Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health. Nat Metab. 2024; 6(10):1922-1938. https://doi.org/10.1038/s42255-024-01126-4.

[16] Bousquet D, Nader E, Connes P, et al. Liver X receptor agonist upregulates LPCAT3 in human aortic endothelial cells. Front Physiol. 2024; 15:1388404. https://doi.org/10.3389/fphys.2024.1388404.

[17] Fang X, Zhang Y, Wang J, et al. Innate immune cell LXR-β deficiency exacerbates hepatic injury and fibrosis in murine models of primary sclerosing cholangitis. Liver Res. 2025; 9(3):239-248. https://doi.org/10.1016/j.livres.2025.09.001.

[18] Jiang C, Ding W, Hu Y, et al. Liver X receptor activation alleviates hepatic ischemia-reperfusion injury in diabetes by inhibiting NF-κB-NLRP3 activation. Immun Inflamm Dis. 2025; 13(8):e70243. https://doi.org/10.1002/iid3.70243.

[19] Clark AT, Russo-Savage L, Ashton LA, et al. A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis. Nat Commun. 2025; 16(1):1102. https://doi.org/10.1038/s41467-025-56565-8.

[20] Lu X, Yuan ZY, Yan XJ, et al. Effects of Angelica dahurica on obesity and fatty liver in mice. Chin J Nat Med. 2016; 14(9):641-652. https://doi.org/10.1016/s1875-5364(16)30076-0.

[21] Gao C, Hu ZH, Cui ZY, et al. Angelica dahurica extract and its effective component bergapten alleviated hepatic fibrosis by activating FXR signaling pathway. J Nat Med. 2024; 78(2):427-438. https://doi.org/10.1007/s11418-024-01780-8.

[22] Zhang J, Zhang Z, Cui T, et al. Prophylactic isoimperatorin protects against LPS-ALI via mTOR-dependent control of inflammation, oxidative stress and ferroptosis markers. J Ethnopharmacol. 2026; 358:120998. https://doi.org/10.1016/j.jep.2025.120998.

[23] Chen L, Yang H, Yu C, et al. High hepatic exposure of furanocoumarins in RadixAngelica dahuricae is associated with transporter mediated active uptake. J Ethnopharmacol. 2018; 212:74-85. https://doi.org/10.1016/j.jep.2017.10.014.

[24] Tang SY, Wang H, Zhang W, et al. Notopterygium forbesii boiss extract and its active constituents increase reactive species and heme oxygenase-1 in human fetal hepatocytes: mechanisms of action. Chem Res Toxicol. 2008; 21(12):2414-2423. https://doi.org/10.1021/tx800301f.

[25] Ko HJ, Park SY, Sim DY, et al. Apoptotic effect of Isoimpertorin via inhibition of c-Myc and SIRT1 signaling axis. Int J Mol Sci. 2024; 25(8):4248. https://doi.org/10.3390/ijms25084248.

[26] Kumar D, Bhat ZA, Kumar V, et al. Coumarins from Angelica archangelica Linn. and their effects on anxiety-like behavior. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40:180-186. https://doi.org/10.1016/j.pnpbp.2012.08.004.

[27] Fuster-Martínez I, Calatayud S. The current landscape of antifibrotic therapy across different organs: a systematic approach. Pharmacol Res . 2024; 205:107245. https://doi.org/10.1016/j.phrs.2024.107245.

[28] Steinberg GR, Carpentier AC, Wang D . MASH: the nexus of metabolism, inflammation, and fibrosis. J Clin Invest. 2025; 135(18):e186420. https://doi.org/10.1172/jci186420.

[29] Taru V, Szabo G, Mehal W, et al. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024; 81(5):895-910. https://doi.org/10.1016/j.jhep.2024.06.016.

[30] Zhu C, Liu Z, Liu H, et al. Hepatocyte cuproptosis promotes the progression of hepatic fibrosis: emerging a potential therapeutic target. Int Immunopharmacol. 2026; 170:116092. https://doi.org/10.1016/j.intimp.2025.116092.

[31] Li T, Huo Y, Ji H, et al. A multifunctional L-arginine-linked melanin nanozyme for theranostic applications in liver fibrosis: non-invasive dual-modal imaging and reactive oxygen species scavenging for pyroptosis suppression. J Colloid Interface Sci. 2026; 702(Pt 1):138872. https://doi.org/10.1016/j.jcis.2025.138872.

[32] Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998; 102(3):538-549. https://doi.org/10.1172/jci1018.

[33] Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 2001; 48(4):548-557. https://doi.org/10.1136/gut.48.4.548.

[34] Wang Y, Gao J, Zhang D, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol. 2010; 53(1):132-144. https://doi.org/10.1016/j.jhep.2010.02.027.

[35] Su TH, Shiau CW, Jao P, et al. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci U S A. 2015; 112(23):7243-7248. https://doi.org/10.1073/pnas.1507499112.

[36] Zhang J, Luan ZL, Huo XK, et al. Direct targeting of sEH with alisol B alleviated the apoptosis, inflammation, and oxidative stress in cisplatin-induced acute kidney injury. Int J Biol Sci. 2023; 19(1):294-310. https://doi.org/10.7150/ijbs.78097.

[37] Sun Z, Liang C, Zhao Y, et al. aHSCs-targeted bimetallic nanozymes and luteolin-loaded liposomes: synergistic reversal of liver fibrosis via antioxidant, cellular senescence, and cellular apoptotic mechanisms. Mater Today Bio. 2025; 34:102201. https://doi.org/10.1016/j.mtbio.2025.102201.

[38] Gayed M, Boraie N, El Achy S, et al. Mannosylated fenretinide loaded solid lipid nanoparticles alleviate liver fibrosis. J Drug Deliv Sci Technol. 2025; 114:107417. https://doi.org/10.1016/j.jddst.2025.107417.

[39] Xiao Y, Zhao C, Tai Y, et al. STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome. Redox Biol. 2023; 62:102691. https://doi.org/10.1016/j.redox.2023.102691.

[40] Chen H, Zhou Y, Hao HP, et al. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies. Chin J Nat Med. 2024; 22(8):724-745. https://doi.org/10.1016/S1875-5364(24)60690-4.

[41] Bai T, Guo HL, Wang F, et al. Gut microbiota and HMGB1/NLRP3/GSDMD inflammasome-dependent pyroptosis: mechanisms by physcion ameliorates alcoholic liver fibrosis. Front Pharmacol. 2025; 16:1532590. https://doi.org/10.3389/fphar.2025.1532590.

[42] Han X, Song J, Lian LH, et al. Ginsenoside 25-OCH₃-PPD promotes activity of LXRs to ameliorate P2X7R-mediated NLRP3 inflammasome in the development of hepatic fibrosis. J Agric Food Chem. 2018; 66(27):7023-7035. https://doi.org/10.1021/acs.jafc.8b01982.

[43] Bai T, Yao YL, Jin XJ, et al. Acanthoic acid, a diterpene in Acanthopanax koreanum, ameliorates the development of liver fibrosis via LXRs signals. Chem Biol Interact. 2014; 218:63-70. https://doi.org/10.1016/j.cbi.2014.04.016.

[44] Zhang J, Yan J, Dong H, et al. Dimeric sesquiterpenoids with anti-inflammatory activities from Inula britannica. Chin J Nat Med. 2025; 23(8):961-971. https://doi.org/10.1016/s1875-5364(25)60931-9.

[45] Sun CP, Zhou JJ, Yu ZL, et al. Kurarinone alleviated Parkinson’s disease via stabilization of epoxyeicosatrienoic acids in animal model. Proc Natl Acad Sci U S A. 2022; 119(9):e2118818119. https://doi.org/10.1073/pnas.2118818119.

[46] Zhang J, Zhang HL, Xu XR, et al. Targeting PBK with small-molecule 1-O-acetyl-4R,6S-britannilactone for the treatment of neuroinflammation. Proc Natl Acad Sci U S A. 2025; 122(29):e2502593122. https://doi.org/10.1073/pnas.2502593122.

[47] Zhang J, Zhang M, Huo XK, et al. Macrophage inactivation by small molecule wedelolactone via targeting sEH for the treatment of LPS-induced acute lung injury. ACS Cent Sci. 2023; 9(3):440-456. https://doi.org/10.1021/acscentsci.2c01424.

[48] Kim DM, Pan Q, Liu Z, et al. GHSR-Foxo1 signaling in macrophages promotes liver fibrosis via inflammatory response and hepatic stellate cell activation. Adv Sci (Weinh). 2025; 12(33):e04223. https://doi.org/10.1002/advs.202504223.